Although anti-EGFR based therapy is commonly prescribed for KRAS wild-type CRC patients, clinical evidence has indicated that the KRAS mutation status alone is insufficient to predict therapeutic response to the therapy (Allegra et al., 2009). Here, KRAS is linked to colorectal carcinoma.